Antigen Drug Valued At $300M
Worcester-based Antigen Express's cancer therapy could be worth more than $300 million, according to an independent firm that specializes in estimating the value of pharmaceutical drugs.
Antigen Express is a wholly-owned subsidiary of Toronto-based Generex Biotechnology Corp., which reiterated in a recent corporate update its intentions to spin Antigen off into its own company. Generex did not provide a timeframe of when that move could happen.
Generex did provide an update on Antigen Express's AE37 drug, which is expected to begin a Phase III clinical trial of the drug's use in treating breast cancer. Antigen Express predicts that the therapy has other uses in treating prostate, ovarian, colon and lung cancers. The $300 million valuation is only based on the drug's breast-cancer use.
Antigen Express has also received preliminary notice of allowance from the U.S. Patent Office to extend protections of AE37 until 2028.
WBJ Web Partners
Most Recent
Most Recent
0 Comments